• Follow us
  • EN
    Flag Indonesia ID
    Flag English EN
Untitled design (6)
  • About Us
    • Company Profile
      • PT Bio Farma (Persero)
      • Kimia Farma Tbk (KAEF)
      • Indofarma Tbk (INAF)
      • PT INUKI (Persero)
    • History
    • Management
      • Commisioners
      • Directors
    • Research & Development
    • Our Achievement
      • Awards
      • Certification
    • Report
      • Annual Report
      • Sustainability
  • Product & Services
    • Our Distribution
    • Product & Services
      • Life Sciences
      • Providers of Health Services & Products
      • Trade, Distribution of Medicines & Medical Devices
    • Immunization Services
    • Cervical Cancer Screening Service
    • FAQ
  • Media & Information
    • News
      • All News
      • Global Roles
      • Products & Services
      • CSR
    • Health Articles
    • Health FAQ
    • Our Procurement
  • Corporation
    • Good Corporate Governance
    • Our Commitment
    • CSR
    • LHKPN
      • Lapor
  • Career
    • Recruitment
  • PPID
  • Contact Us
search

Bio Farma to Explore Immunotherapy Products for Cancer

Monday, 16 December 2019

 

(Jakarta 16/12) Bio Farma has expanded collaboration with two South Korean companie: ForeverNK Inc. and Aribio Co. Ltd. The beginning of this collaboration was signed in  Memorandum of Understanding (MoU) between Bio Farma and two companies based in Seongnam, regarding the exploration and development of potential business opportunities for therapeutic products for cancer treatment.

The products use "NK Cell Therapy" technology will be provided by ForeverNK Inc, meanwhile "NK Cell Conditioned Media" will be obtained from Aribio Co. Ltd.

NK (Natural Killer) Cells are innate lymphoid cells that provide early protection against cancer development by killing abnormal cells in the body that undergo cellular transformation without the need for prior stimulation. NK Cell therapy technology, will be provided by ForeverNK. Meanwhile, NK Cell Conditioned Media is a medium or 'place' for the growth of NK Cells to be made in a tissue culture made by Aribio.

This MoU was signed by the President Director of Bio Farma, Honesti Basyir, Chief Executive Officer ForeverNK, Jung Hoon Oh, and Vice Chariman, Soo-Hyun Sung, on December 16, 2019 in Jakarta.

In his spech, Honesti Basyir said, as state-owned pharmaceutical holding company (per last October 2019) Bio Farma will expand into the pharmaceutical product business especialy in immunotherapy , as the result this MoU.  “This collaboration is the beginning of the initiation of Bio Farma products for immunotherapy, especially for cancer.

As a first step together with two South Korean companies will develop and evaluate market potential opportunities, and set terms and conditions for evaluations related to NK Cell Therapy from ForeverNK and cosmetic products including NK Cell Conditioned Media from ARIBIO. ", said Honesti.

Honesti added, immunotherapy is a type of treatment that encourages our body's own immune system, to be more effective in fighting diseases, including cancer. Bio Farma will play a role in examining and evaluating technologies and products to use them in Indonesia, collabore with hospitals, applying for licenses, and then being marketed in Indonesia through clinical services.

Meanwhile, Fred Kim, representative of Aribio US, said that his party very welcomes to sign this MoU, because Bio Farma and ForeverNK have same philosophy, to dedicate this product for improve teh quality of live and through this give benefit to many people. We hope with this collaboration, will create a product that can be useful for a better life," said Fred. (ed/ss)

  • Share to:
Download

Latest News

WHO 1
Tuesday, 15 September 2026
Bio Farma Achieves 100% in 2026 WHO Accreditation Assessment, Affirming Measles and Rubella Laboratory Competence
Bio Farma
Friday, 11 September 2026
Bio Farma Wins Indonesia Most Reputable Companies Award 2026, Reinforcing Reputation Built on Capability and Trust
Bio Rotavirus
Thursday, 3 September 2026
Bio-RV, a Neonatal Rotavirus Vaccine Developed Through Bio Farma–MCRI Collaboration, Receives Marketing Authorization from the Indonesian Food and Drug Authority, BPOM
View more

Logo biofarma

Call Center 1500810

Head Office

Jl. Pasteur No. 28, Bandung 40161,
Jawa Barat Indonesia
+62 22-2033755
+62 22 - 2041306
mail@biofarma.co.id

Breeding Facility Bio Farma

Jl. Kolonel Masturi Kav 10. Desa Kertawangi kec. Cisarua
Jawa Barat

Bio Farma Representative Office

Gd. Pakarti centre Lantai 7
Jln. Tanah Abang 3 no.23-27
Jakarta Pusat

Information

  • Good Corporate Governance
  • Our Procurement
  • FAQ
  • Vaccine Production
  • Your Career

 

  • Contact Us
  • E-PPID
  • Announcement
  • Media Release

Quick Links

  • Portal BUMN-Bio
  • Kemenkes RI
Copyright © 2026. All Rights Reserved by Bio Farma

Change Language

EN
  • About Us
    • Company Profile
      • Company Profile
      • PT Bio Farma (Persero)
      • Kimia Farma Tbk (KAEF)
      • Indofarma Tbk (INAF)
      • PT INUKI (Persero)
    • History
    • Management
      • Commisioners
      • Directors
    • Research & Development
    • Our Achievement
      • Awards
      • Certification
    • Report
      • Annual Report
      • Sustainability
  • Product & Services
    • Our Distribution
    • Product & Services
      • Life Sciences
      • Providers of Health Services & Products
      • Trade, Distribution of Medicines & Medical Devices
    • Immunization Services
    • Cervical Cancer Screening Service
    • FAQ
  • Media & Information
    • News
      • All News
      • Global Roles
      • Products & Services
      • CSR
    • Health Articles
    • Health FAQ
    • Our Procurement
  • Corporation
    • Good Corporate Governance
    • Our Commitment
    • CSR
    • LHKPN
      • Lapor
  • Career
    • Career
    • Recruitment
  • PPID
  • Contact Us
  • Follow us
Change Language
  • Flag Indonesia ID
  • Flag English EN